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Onchocerciasis, also known as river blindness, is a parasitic disease. More than 99 percent
of all cases occur in Africa. Bioko Island (Equatorial Guinea) is the only island endemic for
onchocerciasis in the world. Since 2005, when vector Simulium yahense was eliminated,
there have not been any reported cases of infection. This study aimed to demonstrate that
updated WHO criteria for stopping mass drug administration (MDA) have been met.
Methodology/Principal findings
A cross-sectional study was conducted from September 2016 to January 2017. Participants
were 5- to 9-year-old school children. Onchocerciasis/lymphatic Filariasis (LF, only in
endemic districts) rapid diagnostic tests (RDTs) were performed. Blood spots were collected
from RDT positive children and 10 percent of the RDT negatives to determine Ov16 and
Wb123 IgG4 antibodies through enzyme-linked immunosorbent assay (ELISA). Skin snips
were collected from RDT positives. Filarial detection was performed by PCR in positives
and indeterminate sera. Black fly collection was carried out in traditional breeding sites. A
total of 7,052 children, ranging from 5 to 9 years of age, were included in the study. Four chil-
dren (0.06%) were Ov16 IgG4 RDT positives, but negative by ELISA Ov16, while 6 RDT
negative children tested positive by ELISA. A total of 1,230 children from the Riaba and
Baney districts were tested for LF. One child was Wb123 RDT positive (0.08%), but ELISA
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negative, while 3 RDT negative children were positive by Wb123 ELISA. All positive sam-
ples were negative by PCR for onchocerciasis and LF (in blood spot and skin snip). All fly
collections and larval prospections in the traditional catching and prospection sites were
negative.
Conclusions/Significance
WHO criteria have been met, therefore MDA in Bioko Island can be stopped. Three years of
post-treatment surveillance should be implemented to identify any new occurrences of
exposure or infection.
Author summary
Onchocerciasis, commonly called river blindness, is a chronic parasitic disease particu-
larly prevalent in Africa. It is transmitted through the bites of infected Simulium blackflies.
Onchocerciasis is endemic in Equatorial Guinea. Huge achievements have been made in
human and vector control during the last two decades, especially on Bioko Island. Elimi-
nating onchocerciasis transmission on Bioko is feasible given its isolation from other
landmasses, which also reduces the risk of reinvasion by the disease vector. Recently
updated WHO guidelines for stopping mass drug administration (MDA) and verifying
elimination of human onchocerciasis (2016) established a new critical threshold to verify
elimination of onchocerciasis transmission based on novel serological tests. We applied
these techniques in a representative sample of 5- to 9-year-old school children. An ento-
mological assessment was also carried out. We found no evidence of current infection or
recent transmission. There was no evidence of onchocerciasis vectors, and our results
from the sample population meet the current WHO serologic criteria for stopping MDA.
Based on these results, we recommended to the Ministry of Health and Social Welfare of
Equatorial Guinea that MDA on Bioko Island be stopped and that 3 years of post-treat-
ment surveillance should be undertaken to identify any new occurrences of exposure or
infection.
Introduction
Onchocerciasis is a parasitic disease caused by the filarial worm Onchocerca volvulus. It is
transmitted through the bites of infected Simulium blackflies, which breed in fast-flowing
streams and rivers. Symptoms include rashes, severe itching and various skin lesions, and
blindness. The disease is endemic in 31 countries in sub-Saharan Africa, two countries in
Latin America, and in Yemen. An estimated 18 million people are infected with the disease
and have dermal microfilariae. 99% of the infected individuals live in Africa [1,2].
Human onchocerciasis is one of the two filarial helminth “neglected tropical diseases” tar-
geted for geographically local elimination [3]. In the Americas, onchocerciasis elimination
has traditionally been considered feasible as most onchocerciasis foci were confined and usu-
ally small. Since 2013, the World Health Organization (WHO) has certified four countries in
Latin America as free of human onchocerciasis [4]. In Africa, where onchocerciasis has been
endemic over vast areas, with highly efficient vectors and much higher endemicity levels, elim-
ination was not initially considered to be feasible [5].
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The Onchocerciasis Control Programme in West Africa (OCP) was launched in 1974 by
the World Health Organization (WHO), followed by the African Programme for Onchocerci-
asis Control (APOC), initiated in 1995. Both programs established mass treatment with iver-
mectin combined with aerial spraying of breeding sites with selected insecticides in fast-
flowing rivers as principal methods for controlling onchocerciasis [3]. Great progress has been
made towards elimination. In most OCP/APOC countries, nationwide onchocerciasis elimi-
nation now seems to be an obtainable objective [6]. This paradigm shift from control to elimi-
nation occurred in 2012 due to success in Latin America, the shift to integrated NTD control,
and the successful elimination of onchocerciasis in some parts of Africa [7].
The island of Bioko is part of the Republic of Equatorial Guinea and is the only island in the
world where onchocerciasis is endemic [8]. Initially, the island was considered free of loiasis.
The presence of intermediate hosts [9], and the recent reporting of an imported case of loiasis
in a US traveler returning from the island [10] call for attention and further research. Two out
of four districts have reported cases of Lymphatic Filariasis (LF). In 1990, several control activi-
ties were launched by the OCP, including long-term ivermectin mass treatment in all 52 island
communities [11,12]. Afterwards, APOC became the sponsoring agency and introduced com-
munity-directed treatment with ivermectin (CDTI) throughout the island in 2000 [8]. In addi-
tion, a vector elimination project started when APOC was established in 1995. A feasibility
study was carried out in 1996, confirming the high vectorial efficiency of the endemic Bioko
form of Simulium yahense [13] and the distribution of the vector breeding sites [14]. From
2001 to 2005, a large-scale larviciding trial using ground-based applications was undertaken
using helicopter and ground-based applications of temephos [8,15]. In 2005, the endemic
Bioko form of S. yahense was finally eliminated from the island. Since then, there has not been
any reported transmission or any serious epidemiological situation in Malabo City or else-
where on the island [8]. According to personal communication from the Ministry of Health
and Social Welfare of Equatorial Guinea (MINSABS in Spanish), the last MDA with ivermec-
tin was administered in 2012 in urban Malabo and in 2016 elsewhere on the island.
A 2014 cross sectional study found no positive MF skin snip assessment in 544 study partic-
ipants ages 5 years and older [16,17]. In the recently updated WHO guidelines for stopping
mass drug administration and verifying elimination of human onchocerciasis (2016), new
tools were proposed to verify the transmission interruption, stop CDTI and begin post-treat-
ment surveillance. Following the WHO updated recommendations, the objectives of this study
were: a) to verify onchocerciasis transmission interruption in Bioko Island, Equatorial Guinea;
b) to validate a methodology to assess Ov16 prevalence in children younger than 10 years of
age and; c) to develop a protocol to verify onchocerciasis elimination that can be applied in
other African countries with hypoendemic intensity of transmission or where mass drug
administration (MDA) has been conducted for a number of years. Data on LF were also col-
lected as part of the study.
Methods
Study area
The Island of Bioko is part of the Republic of Equatorial Guinea, which also includes Rio
Muni on the mainland and the island of Annobon. It is located in the Bay of Guinea in Central
Africa, about 40 km southwest of the Cameroon coast. Bioko Island covers an area of approxi-
mately 2,017 km2 (779 square miles). It is 72 km (44.7 miles) long and is divided into four
districts (Malabo, Luba, Riaba and Baney). Bioko Island has 334,463 inhabitants. Most of the
population is concentrated on the northern part of the island in the Malabo district, where
Malabo, the capital of Equatorial Guinea is located [18]. Tropical rainforest covers much of the
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interior of the island and the topography is characterized by steeply sloping volcanoes and cal-
deras. Bioko Island has a humid tropical climate with an average annual temperature of 25˚C
and two distinct seasons: a dry season from November to March and a rainy season from April
to October.
Study design and participants
A cross-sectional study was conducted from September 2016 to January 2017. The eligible par-
ticipants were 5- to 9-year old school children who had lived in Bioko Island for the past three
years. According to the most recent WHO guidelines, a sample size of 1,100 to 2,000 children
younger than 10 years of age per administrative unit is required for Ov-16 serology testing in
order to detect a prevalence of less than 0.1% at the upper bound of the 95 percent confidence
interval. When the eligible population of children is less than 1,100, all eligible children are to
be tested [19].
First, we obtained an updated census report on school-aged children from the Ministry of
Education. According to this data, sampling was not required in two districts (Riaba and
Luba), since the population was below 1,100. All the children from the Baney district and rural
Malabo who met the inclusion criteria were included in the study because the numbers were
lower than first estimated. In urban Malabo, a random sampling method was implemented.
A second visit took place in May 2017 to obtain a second RDT and blood spot for ELISA/
PCR in patients whose results were RDT/ELISA positives and/or were in the detection thresh-
old limit.
Entomological surveys were carried out in the rivers with potential breeding sites.
Procedures
Two teams, consisting of three local technicians, one supervisor and two coordinators were
assembled and trained before the field work began.
Prior to starting the study, a comprehensive field training program was provided along
with training on the proper use of diagnostic tools. The participation questionnaire was pre-
tested one week before the beginning of the project. Questionnaires were provided to each
school administrator, who distributed them to the children before the science team came to
the school to conduct the testing. Children were instructed to take the forms home and have
their parents or guardians complete them before they were returned. At least two reminders
were given before the testing date. The form required the participant’s sex, birthdate, age, and
asked whether the child had lived in Bioko Island for the past three years and if the child had
ever take ivermectin. Test results were later recorded in the same document.
The geographic coordinates of each school (latitude and longitude) were collected using the
offline maps application MAPS.ME.
This study combined the use of serological tests based on recombinant antigens with the
later confirmation of diagnostic results by molecular diagnosis. The SD BIOLINE Onchocerci-
asis IgG4 rapid diagnostic test, manufactured and distributed by Standard Diagnostics, Inc.
(SD), was performed following the product instructions. Further information on this tech-
nique has been described elsewhere [20]. Sterile techniques were used to obtain finger-prick
blood samples. Fingers were cleaned using an alcohol swab and sterile cotton balls. Techni-
cians wore disposable gloves. All materials were safely disposed of. In those districts consid-
ered co-endemic to lymphatic Filariasis and onchocerciasis (Riaba and Baney), SD BIOLINE
LF IgG4 RDT was also performed, together with SD BIOLINE onchocerciasis/LF IgG4 biplex.
Blood spots were collected from all the children with either a positive Ov RDT or a pos-
itive LF RDT and from a random sample of 10 percent of the negative RDT children for
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determination of Ov16 and Wb123 IgG4 antibodies through enzyme-linked immunosor-
bent assay (ELISA). This subsample (10% of negative RDT) was randomly selected by
equal probability systematic sampling. Every tenth RDT negative child was selected for
further blood spots collection.
Sterile techniques were used to place finger-prick blood spots onto circles on 5 x 5 cm
Whatman 903 protein saver cards. Skin samples were obtained near the iliac crest of each indi-
vidual through Walser matrix forceps. Samples, stored and transported at 4˚C, were delivered
to the National Center of Microbiology (NCM) laboratory at the Institute of Health Carlos III
in Madrid for further analysis.
An ELISA protocol was run to detect anti-Ov16 IgG4 antibodies in the eluted blood from
the Whatman filter paper (S1 ELISA Protocol). Plates were sensitized with 0.5 μg/ml of Ov16
recombinant protein, obtained and purified as described in Hernández-Gónzalez et al., 2016
[16]. A poly-His tail was added to the carboxy-terminus of the Ov-16 sequence amplified from
a vector (kindly donated by Professor JE Bradley, School of Life Sciences and University of
Nottingham, UK). Then, the construction was subcloned into pGEX-6P-1 plasmid (GE
Healthcare, Little Chalfont, UK). Further expression and purification steps were undertaken as
explained in the indicated paper. Two positive controls were included: (i) an anti-Ov16
human recombinant monoclonal antibody (hIgG4, Bio-Rad) and (ii) a pool of positive sera
from patients with onchocerciasis (clinical and parasitological confirmation). A standard
curve from each positive control was used to identify positive samples on each plate allowing
comparisons among plates and days. The anti-Ov16 IgG4 mAb positive control was diluted as
follows: 12, 6, 3, 2, 1.5 and 1 ng/ml and in the case of the positive sera, pool dilutions ranked
from 1/400 to 1/3.200. The cut- off for the recombinant positive control (anti-OV16 mAb;
stock: 2.9 mg / ml), was set at 2.01 ng / ml following the indications of Golden et al., 2017 [21].
The dilution 1/800 from the pool of positive sera was chosen as the cut-off, with optical densi-
ties similar to those obtained with the anti-Ov16 mAb at 2.01 ng/ml.
A similar ELISA protocol was run to detect anti-Wb123 IgG4 antibodies. The only differ-
ence in methodology was that wells were sensitized with Wb123 recombinant protein. The
Wb123- pUC57 construction, corresponding to the GenBank HQ438580 sequence, was
obtained from Genscript (Piscataway, NJ, USA) and further directionally subcloned in pQE-
30 expression vector. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 0.01 mM was used to
induce protein expression with ON incubation at 16˚C. The Wb123 recombinant protein was
purified by Ni2+- Sepharose 4B affinity chromatography (GE Healthcare) in native conditions
and according to the manufacturer’s recommendations. Finally, the Wb123 recombinant anti-
gen was dialyzed against PBS and quantified using the Pierce BCA Protein Assay Kit (Thermo
Scientific Rockford, IL, USA). A standard curve was developed; in this case, with serial dilu-
tions (1/400 to 1/3,200) of a Wuchereria bancrofti positive sera pool (WHO collection provided
by Dr. N. Weiss, Swiss Tropical Institute, Basel). The chosen cut-off was the OD correspond-
ing to the 1/1600 control sera dilution.
In both ELISAs (Ov16 and Wb123), the sera were classified as positive, indeterminate or
negative, following the criteria described below:
• Indeterminate sera: those with an Optical density (O.D.) ± 10 percent of cut-off value (gray
area).
• Positive sera: those with an O.D. above the upper limit of the gray area.
• Negative sera: those with an O.D. below the lower limit of the gray area.
Molecular protocols (PCR) were undertaken to confirm serological positive samples: blood
spots for FL and onchocerciasis positives and skin snip for Onchocerca positives. DNA
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extraction from skin snips specimens and the blood spots were performed with the QIAamp
DNA mini kit (QIAGEN, IZASA, Madrid). Filarial detection was carried out by two indepen-
dent Polymerase chain reaction (PCR) methods. A real-time PCR, modified by Tang et al.
(2010) [22], targets the internal transcribed spacer in one region of the ribosomal gene (ITS-1),
which enables the identification of positive samples by post reaction analysis by melting tem-
perature (Tm) curve of the amplified fragments (Tm = 77.50˚C ± 1.0˚C) and by the size of the
amplified fragment (344bp for O. volvulus, 312bp for Mansonella spp., 301bp for W. bancrofti
and 286bp for Loa loa) and a conventional PCR targeting of the mitochondrial COI gene [23]
(see further details in S1 Table). All samples were made in duplicate.
PCR products were analyzed by automatic electrophoresis (QIAxcel, QIAGEN, IZASA,
Madrid) or conventional electrophoresis in 2 percent agarose gels stained with Pronosafe (Pro-
nadisa, Madrid). The confirmation of the filarial species was performed by sequencing the
amplified fragment using the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Massachusetts, EEUU) on an ABI PRISM 3700 DNA analyzer (Applied Biosystems,
Massachusetts, USA). Previously, PCR products were purified using the Illustra DNA and Gel
Band Purification Kit (General Electric Healthcare, Little Chalfont, UK). All amplified prod-
ucts were sequenced twice in both directions.
All sites accomplishing APOC experts’ criteria for harboring larvae of the simulids were vis-
ited. Black fly collection was carried out in representative catching sites by one team in each
community, consisting of two fly collectors and a human attractant (human bait). The human
bait method involved having the individual sit in one place barefoot for up to one hour. During
this worktime, the fly collector exposed his legs and caught all landing Simulium flies with the
help of an exhaustor (“pooter”). Collections began, local time, at 0700 and ended at 1700. Col-
lectors received ivermectin 1 week before beginning the collection process.
Statistical analysis
Individual data, RDT and laboratory results were analyzed to obtain frequencies of each vari-
able. Prevalence (with 95 percent confidence intervals) of onchocerciasis and LF were calcu-
lated from RDT results. In three out of the four districts (and rural Malabo), all the eligible
children attending school the day of the visit were included. It was not confirmed whether any
children were absent on the day of the survey or whether any local children were not attending
school at all. Prevalence and confidence limits were computed following the recommendations
of Brown et al. for interval estimation for a binomial proportion [24]. The Wilson interval for
small n (when n<100), and the interval suggested in Agresti and Coull for larger n (when
n100), were used.
A univariate analysis was performed to explore if any variable showed a significant relation-
ship with positive onchocerciasis RDT cases. Analyses were performed using the statistical
package Stata 14.0. Schools were mapped using the free software QGIS version 2.18.7.
Ethics statement
The study was approved by the MINSABS on Bioko Island and the research ethics and animal
welfare committee at the Health Institute Carlos III (ISCIII in Spanish) in Spain, under the
number CEI PI 22_2016-v3. The school headmasters and children´s parents/guardians were
informed of the day of the visit and the scope of the study by an official letter from the MIN-
SABS. Written informed consent was obtained from all parents or guardians prior to study
inclusion. Data were analyzed anonymously.
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Results
A total of 7,052 school children, ages 5 to 9 years old and living in Bioko Island for the last
three years or more, participated in the epidemiological assessment. The study sample was
recruited from 147 schools, distributed all around the Island (Fig 1). In the Riaba, Luba and
Baney districts and rural Malabo, all of the eligible 5- to 9-year-old children agreed to partici-
pate and were thus included. In urban Malabo, several parents did not sign the study agree-
ment form (around 25%), and replacements for these individuals were found to obtain a
sample of 4,342 randomly selected children.
The majority of the 5- to 9-year-old children lived in urban Malabo. Overall, ages were
evenly distributed. The sample was 52.4% female. 96 percent of the respondents reported that
their children had never received ivermectin (Table 1).
Onchocerciasis
Finger-prick blood samples for Ov16 IgG4 RDT were obtained from all 7,052 school children.
From the overall sample, four children (0.06 percent) were found to be positive for Ov16 IgG4
antibodies by RDT (95 percent CI upper limit = 0.11). One was from the Riaba district and
three lived in rural Malabo (Fig 2). No significant association with onchocerciasis RDT posi-
tive cases was found for any variable, except for district. Rural Malabo presented the highest
frequency of onchocerciasis RDT positive cases (n = 3; p<0.001).
Blood spots were collected from 720 school children. Five of them were obtained from posi-
tive individuals and 715 (10 percent) were collected from a randomized selection of RDT nega-
tive children. Skin snips were obtained from the RDT positive children (n = 4). The 4
onchocerciasis RDT positive children were negative by ELISA Ov16, while 6 RDT negative
children from urban Malabo tested positive to onchocerciasis by ELISA (prevalence = 0.83
percent; 95 percent CI = 0.34–1.85). Three samples were considered as indeterminate sera,
because they were close to the ELISA cutoff threshold. PCR analysis was negative for all posi-
tive/indeterminate blood and skin samples (n = 13; Table 2).
Lymphatic filariasis
A total of 1,230 children from Riaba and Baney were tested for lymphatic Filariasis. In one
Baney district school (with n = 19), the LF IgG4 RDT was not performed due to logistical prob-
lems. One 9-year-old girl (0.08%) from Baney was found positive for Wb123 by LF IgG4 RDT
(Table 3), while no child tested positive for Wb123, according to onchocerciasis/LF IgG4
biplex results.
Samples were processed by ELISA with recombinant Wb123. The LF RDT positive child
was ELISA negative, while 3 children from Baney and 2 from Riaba who tested negative by
RDT tested positive when sera was processed by Wb123 ELISA (Fig 2). One onchocerciasis
RDT positive child was also positive to LF by Wb123 ELISA. All LF serologically positive chil-
dren (n = 6) were negative by PCR (Table 3).
Verification of results
In May 2007, a second serum sample was obtained from 16 children who were either RDT pos-
itive (Onchocerciasis or LF) or ELISA positive/indeterminate for confirmatory test (n = 18).
Two school children were unavailable during the second visit.
Out of the above population, 2 children were onchocerciasis RDT positive (preva-
lence = 0.03%; 95% CI = 0.00–0.11), 1 by Ov16 IgG4 RDT and the other by Oncho/LF biplex
IgG4 RDT. Both were negative by Ov16 ELISA and blood spot/skin snip PCR. The child, who
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was previously found positive to LF, was negative by biplex RDT in this second round. The
second Ov16-IgG4 ELISA analysis was negative for all the samples (n = 16) except one.
Regarding those samples that were positive by ELISA with recombinant Wb123 in the prelimi-
nary analysis (n = 5), 3 remained positive, 1 became negative and the fifth one had been col-
lected from one of the two unavailable children. Skin snips were obtained from the confirmed
biplex RDT (n = 2) and Ov16 ELISA (n = 1) positive children. PCR analysis was negative for
all of them (Table 4; S2 Table).
Updated WHO guidelines established that serologically positive children found negative by
PCR testing of skin snips are considered negative for patent infection with O. volvulus and are
accepted as not contributory to the 0.1% threshold calculation [19]. According to this
Fig 1. Geographical distribution of participant schools in Bioko Island, September 2016 to January 2017.
https://doi.org/10.1371/journal.pntd.0006471.g001
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criterion, no child was positive for onchocerciasis (Table 2). The 2 RDT and the remaining
ELISA positive child (according to the sera obtained on the second visit) were considered as O.
volvulus “exposed.” The MINSABS will re-examine them 1 to 1.5 years after the first visit to
determine if they have developed patent infection. If so, they will be treated accordingly, fol-
lowing WHO recommendations [19].
Entomological assessment
Entomological assessment was performed from the 29th of August to the 23rd of September,
2016. Due to fieldwork difficulties and the need for extra personnel, the Ureka area (breeding
sites placed in rivers Mohaba, Ehola and Osha) was visited in February 2017 (Fig 3). All fly col-
lection and breeding site prospection were negative.
Discussion
We conducted an evaluation of O. volvulus transmission in Bioko Island, Equatorial Guinea,
guided by updated WHO guidelines [19]. We found no evidence of current infection or recent
transmission: there was no evidence of onchocerciasis vectors, and our results in 5- to 9-year-
old children meet the current WHO 0.1 percent serologic criteria for stopping MDA. More-
over, none of the children tested positive when RDT was combined with ELISA. Based on
these results, we recommended to the Ministry of Health and Social Welfare in Equatorial
Guinea (MINSABS) that MDA in Bioko Island be stopped and that 3 years of post-treatment
surveillance should begin, to identify any new occurrences of exposure or infection.WHO
defines disease elimination as the reduction to zero of the incidence of infection caused by a
specific pathogen in a defined geographical area, with minimal risk of reintroduction, as a
result of deliberate efforts [25]. To measure the progress towards elimination, three phases
have been defined for onchocerciasis control programs. The phase 1 or intervention phase is
characterized by regular ivermectin treatment with a minimum requirement of 80 percent
therapeutic coverage. This phase typically lasts at least 12 to 15 years, which corresponds to the














n % n % n % n % n % n %
Sex Male 3,357 47.60 44 46.3 590 51.1 254 51.5 453 46.8 2,016 46.4
Female 3,695 52.40 51 53.7 564 48.9 239 48.5 515 53.2 2,326 53.6
Age 5 1,305 18.51 16 16.8 160 13.9 75 15.2 205 21.2 849 19.6
6 1,479 20.97 28 29.5 256 22.2 87 17.6 230 23.8 878 20.2
7 1,431 20.29 21 22.1 236 20.5 96 19.5 199 20.6 879 20.2
8 1,519 21.54 15 15.8 264 22.9 128 26.0 165 17.0 947 21.8
9 1,318 18.69 15 15.8 238 20.6 107 21.7 169 17.5 789 18.2
History of ivermectin treatment Yes 283 4.01 1 1.1 74 6.4 15 3.0 47 4.9 146 3.4
No 4,601 65.25 78 82.1 575 49.8 450 91.3 541 55.9 2,957 68.1
Don´t know 2,168 30.74 16 16.8 505 43.8 28 5.7 380 39.3 1,239 28.5
Skin snip specimen collected Yes 4 0.06 1 1.1 0 0.0 0 0.0 3 0.3 0 0.0
No 7,048 99.94 94 98.9 1,154 100.0 493 100.0 965 99.7 4,342 100.0
Whatman paper sample collected Yes, positive RDT 5 0.07 1 1.1 1 0.1 0 0.0 3 0.3 0 0.0
Yes, 10% random of negative RDT 715 10.14 8 8.4 116 10.1 47 9.5 97 10.0 443 10.2
No 6,332 89.79 86 90.5 1,037 89.9 446 90.5 868 89.7 3,899 89.8
https://doi.org/10.1371/journal.pntd.0006471.t001
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reproductive lifespan of the adult worm when exposed to drug pressure [19]. Phase 2, also
called “post-treatment surveillance” follows the intervention phase and typically lasts 3 to 5
Fig 2. Geographical distribution of RDT and ELISA positives in 5- to 9-year-old school children in Bioko Island, September 2016 to January 2017.
https://doi.org/10.1371/journal.pntd.0006471.g002
Table 2. Prevalence of onchocerciasis in children less than 10 years old tested by Ov-16 IgG4 RDT, ELISA and PCR, Bioko Island, September 2016 to January 2017.
Population Onchocerciasis RDT (n = 7,052) Onchocerciasis ELISA Ov16 (n = 720) Onchocerciasis PCR (n = 720)
n Positive Prev. (%) 95% CI n Positive Prev. (%) 95% CI n Positive Prev. (%) 95% CI
Overall population 7,052 4 0.06 (0.02–0.14) 720 6 0.83 (0.34–1.85) 720 0 0 (0.00–0.64)
Riaba 95 1 1.05 (0.18–5.72) 11 0 0 (0.00–25.88) 11 0 0 (0.00–25.88)
Baney 1,154 0 0 (0.00–0.40) 120 0 0 (0.00–3.73) 120 0 0 (0.00–3.73)
Luba 493 0 0 (0.00–0.93) 49 0 0 (0.00–7.27) 49 0 0 (0.00–7.27)
Rural Malabo 968 3 0.31 (0.06–0.95) 96 0 0 (0.00–3.85) 96 0 0 (0.00–3.85)
Urban Malabo 4,342 0 0 (0.00–0.11) 444 6 1.33 (0.55–2.99) 444 0 0 (0.00–1.03)
 3 indeterminate sera were not included as positive; Prev: prevalence; 95% CI: 95% confidence interval; N.P.: not performed.
https://doi.org/10.1371/journal.pntd.0006471.t002
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years. The final phase (phase 3) starts at the end of the 3 to 5 years of post-treatment surveil-
lance and is also known as “post-elimination surveillance.” It follows the confirmation of the
initial assessments at the end of phase 2, thereby providing strong evidence that transmission
has been permanently eliminated in a country. According to our results, Bioko Island is cur-
rently in phase 2. On Bioko Island, initial onchocerciasis control activities began in 1990,
using ivermectin distributed by mobile teams [12,26]. After 8 years, a significant reduction in
onchocerciasis prevalence (from 74.5 to 38.4 percent), and community MF load (from 28.3 to
2.3) [11] was achieved. Afterwards, APOC became the sponsoring agency and introduced
CDTI throughout the island in 2000 [8]. Since then, therapeutic coverage has ranged from 51
[11] to 75 percent [27]. Although the therapeutic coverages have been relatively low, treatment
intervention has been steady for more than 20 years. On the other hand, Equatorial Guinea
(Bioko island in particular) is one of the three African countries (Uganda and the United
Republic of Tanzania being the other two) that supplemented MDA together with vector con-
trol [19]. Furthermore, given that Bioko Island has been free of onchocerciasis vectors for the
past 12 years [3,8] and the insular isolation of Bioko (32 km from the Cameroon coast and 400
km from the Guinean mainland coast), WHO might reconsider if the post treatment surveil-
lance is truly needed in this case.
This study also reports the first use of anti-Ov16 IgG4 RDT in a primary field screening fol-
lowed by confirmatory ELISA/PCR in the laboratory to certify onchocerciasis elimination in
an African endemic area. Several markers for infection have been used for measuring
Table 3. Prevalence of lymphatic filariasis in children younger than 10 years old tested by LF IgG4/biplex RDT, ELISA and PCR, Bioko Island, September 2016 to
January 2017.
Population Lymphatic Filariasis RDT(n = 1,230) Lymphatic Filariasis Wb123 ELISA (n = 131) Lymphatic Filariasis PCR (n = 6)
n Positive Prev. (%) 95% CI n Positive Prev. (%) 95% CI n Positive Prev. (%) 95% CI
Overall population 1,230 1 0.08 (0.00–0.51) 131 5 3.82 (1.64–8.62) 131 0 0 (0.00–3.42)
Riaba 95 0 0 (0.00–3.89) 11 2 18.18 (5.14–47.70) 11 0 0 (0.00–25.88)
Baney 1,135 1 0.09 (0.00–0.55) 120 3 2.50 (0.53–7.41) 120 0 0 (0.00–3.73)
 By LF IgG4 RDT and/or onchocerciasis/LF IgG4 biplex.
PCR was performed in RDT positive (n = 1) and ELISA positives (n = 5).
https://doi.org/10.1371/journal.pntd.0006471.t003









Onchocerciasis RDT 7,052 2 0.03 (0.00–0.11)
Onchocerciasis ELISA Ov16 (10%negative + RDT
positive)
720 1 0.14 (0.00–0.86)
Onchocerciasis PCR (serologically positive) 13 0 0 (0.00–
22.81)-
Lymphatic Filariasis RDT 1230 0 0 (0.00–0.38)-
Lymphatic Filariasis Wb123 ELISA (10%negative + RDT
positive)
131 3 2.29 (0.48–6.81)
Lymphatic Filariasis PCR (serologically positive) 6 0 0 (0.00–
39.03)-
 For the 95% CI estimation, an unknown population was included as denominators
 One previously Wb123 ELISA positive child was unavailable during the second visit.
https://doi.org/10.1371/journal.pntd.0006471.t004
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onchocerciasis disease burden; however, most of them seem to be insensitive to certifying
elimination [28]. Commonly used methods for diagnosing O. volvulus infections (microscopic
detection of microfilariae (MF) in skin snips and nodule palpation) are insensitive, especially
when MF skin densities are low. PCR of the skin snips may provide greater sensitivity but still
require sampling skin snips. Moreover, the cost of performing PCR on entire populations, or
even in sentinel groups, is high [29]. An alternative approach is applying antibody detection to
O. volvulus specific antigens that are expressed by the larval stages of the parasite. This method
seems to be particularly useful to identify incident infections in communities having already
undergone MDA [30]. Several serological markers for exposure to onchocerciasis have been
assessed in the past [31,32]. The most widely used and the one adopted as a tool for monitoring
onchocerciasis control and elimination in the Americas is the Ov-16 antigen [33]. This test has
Fig 3. Entomological survey of potential breeding sites, Bioko Island, September 2016 to February 2017.
https://doi.org/10.1371/journal.pntd.0006471.g003
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been mainly performed by enzyme immunoassay (EIA or ELISA), that detects IgG4 to this
antigen. IgG4 detection results are more reliable than IgG detection, leading to fewer false pos-
itive results, which is critical for its use in a low prevalence, elimination scenario [30]. In Sub-
Saharan Africa, the Ov16 ELISA was used to prove that onchocerciasis transmission was inter-
rupted in the Wadelai focus of Northwestern Uganda [34] and the Abu Hamed focus, in
Sudan [35].
In this new paradigmatic scenario, where elimination seems obtainable, a standardized
affordable, simple and rapid alternative for testing in the field is necessary. To fill this gap, a
new RDT was recently developed by PATH [20,29]. To date, this Ov16 RDT accuracy has been
mainly assessed in surveillance studies and/or African focus with high onchocerciasis preva-
lence. Its usefulness in defining when to stop MDA is still limited [29,36,37]. Our study is the
first one to provide evidence on its accuracy and usefulness in an African focus with low-prev-
alence conditions prevailing at the end-stage of control programs.
Combining this method with other diagnostic strategies (ELISA in 10% of RDT negatives
and RDT positives, and PCR in all seropositives), we also contribute to a better understanding
of the dynamics of Ov16 antibody responses for accurate interpretation of seroprevalence
data. In our study, four children (0.06%) were positive by RDT, but negative by ELISA and
PCR. This prevalence was even lower after verification of results during a second visit (0.03
percent). Regarding the Onchocerciasis and Lymphatic Filariasis IgG4 biplex RDT, it also per-
formed well in the present study. One positive child out of 1,230 (0.08 percent) was deemed
negative by ELISA and PCR. The integration of two filarial antigens in one device is of added
value in co-endemic areas where MDA has been ongoing for several years. It saves time,
money, and human resources in regions where co-endemicity is suspected. Nevertheless, it
may not provide accurate results in areas that are highly endemic for loiasis [38], which was
not the case on Bioko Island. Therefore, the high sensitivity and specificity shown by both
RDTs support their usefulness to determine the interruption of onchocerciasis transmission.
In summary, we have developed and tested a protocol for stopping MDA and evaluating
onchocerciasis elimination following the updated WHO guidelines [19]. Its implementation
on Bioko Island has been a success, but some considerations should be taken into account
before applying it to other African countries. Previous research has proven that onchocerciasis
elimination with ivermectin treatment might be feasible in some endemic foci in Africa
[39,40]. In Bioko island, MDA was quite successful, but interruption of the disease transmis-
sion might have been partially or completely due to the disappearance of the Simulium vectors,
as was the case in Uganda [34]. In the case of this study, the elimination of the vector, com-
bined with the isolated nature of Bioko and the long history of MDA, were responsible for a
particularly low baseline level. This should be taken into account before using this protocol in
other contexts.
Limitations and conclusions
Our study has several limitations. First, the lower participation rate in urban Malabo may
affect the interpretation of the results in this particular district. Moreover, the school atten-
dance rates for 5- to 9-year-old children were not provided by the Ministry of Education
(probably this information is not systematically recorded). Nevertheless, the sample size was
larger than would have been required in this administrative unit according to the WHO guide-
lines. Second, the recombinant positive control antibody AbD19432_hIgG4 was complex to
standardize, due to the reagent instability when it was diluted to the final concentration to be
used in ELISAs. Secondary extractions from indeterminate serological samples (within the
detection limit threshold) were obtained in May 2017 to verify the results. Only one of the
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conflictive samples requested yielded a positive absorbance value by both positive controls
(recombinant control and serum control). Third, pre-analytical bias due to the complex field
logistics might exist. To reduce these potential biases, detailed guideline and standard opera-
tional procedures (SOPs) were prepared and piloted prior to the field work. All the SOPs were
also tested by internal control before and during the field work.
In conclusion, WHO criteria have been met in Bioko Island. Consequently, MDA can be
stopped and 3 years of post-treatment surveillance should begin to identify any new occur-
rences of exposure or infection. Successful elimination of onchocerciasis infection throughout
Equatorial Guinea may be a feasible goal for the relatively near future. To that end, a survey
extending to the continental area is needed before talks about countrywide elimination begin.
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3. Tekle AH, Zouré HGM, Noma M, Boussinesq M, Coffeng LE, Stolk WA, et al. Progress towards oncho-
cerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control:
epidemiological evaluation results. Infect Dis Poverty. 2016; 5: 66. https://doi.org/10.1186/s40249-016-
0160-7 PMID: 27349645
4. World Health Organization (WHO). Weekly Epidemiological Record (WER), 10 November 2017, vol.
92, 45 (pp. 681–700) [EN/FR]. In: ReliefWeb [Internet]. [cited 11 Dec 2017]. Available: https://reliefweb.
int/report/world/weekly-epidemiological-record-wer-10-november-2017-vol-92-45-pp-681-700-enfr
5. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis.
Filaria J. 2003; 2: 1. https://doi.org/10.1186/1475-2883-2-1
6. African Programme for Onchocerciasis Control (APOC), World Health Organization (WHO). Report of
the Fortieth Session of the Technical Consultative Committee (TCC) [Internet]. 2015. Available: http://
www.who.int/apoc/media/TCC40_Final_report_30_04_2015.pdf?ua=1
7. Mackenzie CD, Homeida MM, Hopkins AD, Lawrence JC. Elimination of onchocerciasis from Africa:
possible? Trends Parasitol. 2012; 28: 16–22. https://doi.org/10.1016/j.pt.2011.10.003 PMID: 22079526
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40. Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elim-
ination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Sene-
gal. PLoS Negl Trop Dis. 2009; 3: e497. https://doi.org/10.1371/journal.pntd.0000497 PMID: 19621091
Onchocerciasis transmission interruption in Bioko Island, Equatorial Guinea
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006471 May 3, 2018 17 / 17
